AMLN » Topics » If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.

This excerpt taken from the AMLN 10-K filed Feb 26, 2010.

         If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

        Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

This excerpt taken from the AMLN 10-Q filed May 11, 2009.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

 

Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

 

These excerpts taken from the AMLN 10-K filed Feb 27, 2009.

         If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

        Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

        
If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.



        Certain of our research and development programs for drug candidates are at an early stage and will require significant research,
development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether
our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.




This excerpt taken from the AMLN 10-Q filed Nov 4, 2008.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

 

Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization.  We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

 

This excerpt taken from the AMLN 10-Q filed Jul 31, 2008.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

 

Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization.  We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

 

This excerpt taken from the AMLN 10-Q filed May 2, 2008.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

 

Certain of our research and development programs for drug candidates are at an early stage and will require significant

 

27



 

research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization.  We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

 

These excerpts taken from the AMLN 10-K filed Feb 27, 2008.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

 

Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization.  We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

 

If our research and development programs fail to result in
additional drug candidates, the growth of our business could be impaired.



 



Certain of our research
and development programs for drug candidates are at an early stage and will
require significant research, development, preclinical and clinical testing,
manufacturing scale-up activities, regulatory approval and/or commitments of
resources before commercialization.  We
cannot predict whether our research will lead to the discovery of any
additional drug candidates that could generate additional revenues for us.



 



This excerpt taken from the AMLN 10-Q filed Nov 6, 2007.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

 

Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

 

This excerpt taken from the AMLN 10-Q filed Aug 7, 2007.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

This excerpt taken from the AMLN 10-Q filed May 2, 2007.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

This excerpt taken from the AMLN 10-K filed Feb 26, 2007.

If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.

Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.

This excerpt taken from the AMLN 10-Q filed Nov 6, 2006.

If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.

Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.

This excerpt taken from the AMLN 10-Q filed Aug 7, 2006.

If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.

Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.

This excerpt taken from the AMLN 10-Q filed May 5, 2006.

If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.

 

Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.

 

This excerpt taken from the AMLN 10-K filed Mar 7, 2006.

If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.

 

Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.

 

This excerpt taken from the AMLN 10-Q filed Nov 7, 2005.

If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.

 

Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.

 

This excerpt taken from the AMLN 10-Q filed Aug 8, 2005.

If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.

 

Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki